Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of recombinant anti-IL-4Rα humanized monoclonal antibody injection (611) in moderate-to-severe COPD in China
CTR20233192Phase 2Completed
- Sponsor
- 3S Guojian Pharmaceutical
- Start
- Oct 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of SSGJ-611 in chronic obstructive pulmonary disease (COPD), sponsored by 3S Guojian Pharmaceutical. Started Oct 2023; status: completed.
02
Drugs
SSGJ-611
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on CTR20233192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233192.